Werewolf Therapeutics Faces Regulatory and Financial Challenges Amid FDA Disruptions

Werewolf Therapeutics, Inc. (HOWL) has disclosed a new risk, in the Regulation category.

Werewolf Therapeutics, Inc. faces significant business risks due to potential disruptions at the FDA and other government agencies stemming from funding cuts, personnel losses, and regulatory reforms. The recent reduction in force and budget cuts at the FDA, along with executive orders from the Trump administration, could delay the guidance and approval processes critical for the company’s clinical development programs. Such disruptions may hinder the timely development and approval of Werewolf’s product candidates, negatively impacting their business operations. Additionally, government shutdowns and public health emergencies could further exacerbate these challenges, affecting the company’s ability to secure necessary capital and continue its operations.

The average HOWL stock price target is $4.67, implying 253.79% upside potential.

To learn more about Werewolf Therapeutics, Inc.’s risk factors, click here.